Sir,
Mammalian hepadnaviruses such as hepatitis B virus (HBV) and woodchuck hepatitis virus (WHV) contain a conserved post-transcriptional regulatory element (PRE) that is required for the cytoplasmic accumulation of mRNAs encoding the virion surface antigen. These PREs confer enhanced gene expression when linked with heterologous transcription units and a PRE derived from WHV (WPRE) has proven to be particularly effective. 1 The WPRE has been incorporated into a number of viral vectors, including those based on retroviruses, adenoassociated viruses and lentiviruses with significant beneficial effects on transgene expression. 2, 3 In our work with lentiviral vectors based on equine infectious anemia virus (EIAV), we have incorporated a WPRE into a number of vectors and demonstrated enhanced expression (unpublished data; O'Rourke et al, 4 Bienemann et al). 5 The WPRE element that we have used comprises nucleotides 1093-1685 (nucleotide numbering scheme of GenBank accession no. J04514) and contains the tripartite element that has been shown to be essential for enhanced gene expression. The fragment also contains an enhancer element, We1, a promoter for the WHV X protein and the sequence for the first 60 amino acids of the X protein. These sequences overlap the functional PREs. The WPRE therefore has potential promoter activity and the potential to express a 60 amino-acid X protein-derived peptide.
The hepadnavirus X proteins are highly conserved B150 amino-acid proteins that appear to share biological properties. They are multifunctional and can activate and repress transcription of a number of cellular and viral genes, and have antiapoptotic, proapoptotic, antiproliferative and proliferative activities depending on the assay system (Kim et al 6 and references cited therein). It has been suggested that the X protein is pivotal to the generation of liver cancers, which are a very common consequence of infection with HBV in man and infection by WHV in woodchucks, reaching a 40% incidence in the latter (Höhne et al, 7 Schuster et al 8 and references cited therein). We have considered whether the presence of promoter/enhancers and X protein-coding sequences in the WPRE could have any safety implications in the clinical application of vectors. Many studies have suggested that the X promoter is nonfunctional in the absence of a second enhancer, We2/En2 (WHV/HBV), 9 which is not present in the PRE, and this has been confirmed recently in the context of a lentiviral vector. 10 Consequently, there seems to be a low probability that there would be any significant expression directed by this promoter. There is some controversy in the literature about the role of the X protein in hepadnavirus-induced cancers. The expression of the X protein does not appear to be directly oncogenic, but there are studies that show that under some circumstances it can act as a weak cofactor for oncogenesis; for example, in combination with cellular oncogenes (reviewed in Terradillos et al).
11 There are also reports that suggest that X proteins truncated at the carboxy-terminus may have a greater oncogenic potential than full-length proteins. 12 Furthermore, it has been noted that in human hepatocellular cancers, where there is a high frequency of integrated HBV sequences, there are usually deletions and mutations of the X ORF. These naturally deleted and mutated proteins are more active in increasing cellular proliferation than the wild-type proteins. 13 The deletions in HBV commonly occur across direct repeats called DR1 and DR2 and analogous repeats exist in WHV. The DR elements are located in the X ORF such that deletion would remove all amino acids beyond amino acid 72 in both HBV and WHV. The remaining N-terminal 72 aminoacid fragment of the X protein is highly conserved between HBV and WHV and contains a presumptive protein interaction site that that has been shown to be involved in auto-regulation of the X protein.
14 There remains the possibility, however, that this domain has some other function in the cell and that this function could be linked to the development of the tumour phenotype.
There is no direct experimental evidence that the Nterminal 72 amino-acid fragment of the X-protein is oncogenic and there appears to be a low probability that it would be expressed from the X promoter that is present in the WPRE. However, the possibility of expression directed by other promoter/enhancers contained within a particular vector or at chromosomal integration sites cannot be excluded. Also, the possibility that the truncated X protein fragment has biological activity, potentially related to tumour development, cannot be excluded. In developing EIAV-based vectors for clinical application, we have therefore modified the WPRE to ablate the promoter and the translation initiation site to prevent any expression of X-protein fragments. Such modified WPREs still enhance gene expression and we have reported efficacy in animal studies with these vectors. 15 We are currently investigating the oncogenic potential of the WPRE. However, we considered that before these studies were completed it would be helpful to alert gene therapy researchers to the potential safety issues surrounding the use of an unmodified WPRE in their vectors. 
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